Literature DB >> 16765251

Granulocyte-macrophage colony-stimulating factor stimulates arteriogenesis in a pig model of peripheral artery disease using clinically applicable infusion pumps.

Sebastian Grundmann1, Imo Hoefer, Susann Ulusans, Christoph Bode, Stephen Oesterle, Jan G Tijssen, Jan J Piek, Ivo Buschmann, Niels van Royen.   

Abstract

BACKGROUND: A growing number of patients suffer from peripheral artery disease (PAD). Current therapies are often limited by the extent of vascular pathology and the occurrence of restenosis after angioplasty. The stimulatory effect of growth factor administration on collateral vessel formation (arteriogenesis) has evolved as a potential new treatment for this patient group. Granulocyte-macrophage colony-stimulating factor (GM-CSF) was shown to stimulate arteriogenesis in small-animal models and in a pilot study in patients with coronary artery disease. Although a recent clinical study demonstrated disappointing results after subcutaneous GM-CSF application in patients with PAD, we hypothesized that intra-arterial cytokine application using implantable infusion pumps might well stimulate arteriogenesis in a large-species model of peripheral vascular disease. We also aimed to compare continuous and intermittent infusion regimens and to validate experimental and clinically available measurements of collateral artery growth.
METHODS: Twenty-four pigs underwent unilateral occlusion of the right femoral artery and received either GM-CSF continuously, GM-CSF intermittently, or phosphate-buffered saline (PBS). After 1 week, collateral conductance was determined under maximal vasodilatation with adenosine and by using a pump-driven extracorporal shunt system.
RESULTS: Conductance showed a significant stimulatory effect of GM-CSF on arteriogenesis (collateral conductance [mL/min/mm Hg]: PBS, 37.7 +/- 5.4; GM-CSF continuous, 69.2 +/- 12.5; GM-CSF intermittent, 71.5 +/- 11.1). Flow measurements under reactive hyperemia were consistent with these results (flow occluded/non-occluded hind limb: PBS, 40.5% +/- 9.1%; GM-CSF continuous, 48.9% +/- 3.9%; GM-CSF intermittent, 48.7% +/- 4.4%). Measurements of ankle/brachial indices were not sensitive enough to detect the differences in collateral growth between the three groups.
CONCLUSION: These results demonstrate the proarteriogenic properties of GM-CSF in larger animal species, revealing comparable efficacy of continuous and intermittent intra-arterial infusion. Furthermore, we provide evidence that implantable pumps offer a possible means for the intra-arterial application of growth factors. Intra-arterial application of GM-CSF might be a future treatment option for vascular occlusive disease. Finally, we show that in the peripheral circulation, pressure measurements alone have a low sensitivity to determine the effects of proarteriogenic therapy compared with flow or combined flow-pressure measurements.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16765251     DOI: 10.1016/j.jvs.2006.02.049

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

Review 1.  Vascular Regeneration in Peripheral Artery Disease.

Authors:  John P Cooke; Shu Meng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-05-21       Impact factor: 8.311

Review 2.  With a Little Help From My Friends: the Role of the Renal Collateral Circulation in Atherosclerotic Renovascular Disease.

Authors:  Jakob Nyvad; Amir Lerman; Lilach O Lerman
Journal:  Hypertension       Date:  2022-02-09       Impact factor: 10.190

3.  An endovascular model of ischemic myopathy from peripheral arterial disease.

Authors:  Chandler A Long; Lucas H Timmins; Panagiotis Koutakis; Traci T Goodchild; David J Lefer; Iraklis I Pipinos; George P Casale; Luke P Brewster
Journal:  J Vasc Surg       Date:  2016-09-29       Impact factor: 4.268

Review 4.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

5.  Vascular growth in health and disease.

Authors:  Anja Bondke Persson; Ivo R Buschmann
Journal:  Front Mol Neurosci       Date:  2011-08-24       Impact factor: 5.639

6.  A Swine Hind Limb Ischemia Model Useful for Testing Peripheral Artery Disease Therapeutics.

Authors:  Juline N Deppen; Sydney C Ginn; Na Hee Kim; Lanfang Wang; Ronald J Voll; Steven H Liang; Mark M Goodman; John N Oshinski; Rebecca D Levit
Journal:  J Cardiovasc Transl Res       Date:  2021-05-28       Impact factor: 4.132

7.  The effects of transfection reagent polyethyleneimine (PEI) and non-targeting control siRNAs on global gene expression in human aortic smooth muscle cells.

Authors:  Nurazhani A Raof; Deepa Rajamani; Hsun-Chieh Chu; Aniket Gurav; Joel M Johnson; Frank W LoGerfo; Leena Pradhan-Nabzdyk; Manoj Bhasin
Journal:  BMC Genomics       Date:  2016-01-05       Impact factor: 3.969

8.  Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single-Domain Llama-Derived Antibody.

Authors:  Maurits R Hollander; Matthijs F Jansen; Luuk H G A Hopman; Edward Dolk; Peter M van de Ven; Paul Knaapen; Anton J Horrevoets; Esther Lutgens; Niels van Royen
Journal:  J Am Heart Assoc       Date:  2019-10-09       Impact factor: 5.501

9.  Anti-Galectin-2 Antibody Treatment Reduces Atherosclerotic Plaque Size and Alters Macrophage Polarity.

Authors:  Jamie Kane; Matthijs Jansen; Sebastian Hendrix; Laura A Bosmans; Linda Beckers; Claudia van Tiel; Marion Gijbels; Noam Zelcer; Carlie J de Vries; Philipp von Hundelshausen; Marc Vervloet; Ed Eringa; Anton J Horrevoets; Niels van Royen; Esther Lutgens
Journal:  Thromb Haemost       Date:  2022-02-08       Impact factor: 6.681

Review 10.  New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease.

Authors:  Brian H Annex; John P Cooke
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.